ERK inhibitors and uses thereof
The present invention provides compounds, compositions thereof, and methods of using the same.
1. A compound of the following structure:
or a pharmaceutically acceptable salt thereof.
2. A composition comprising the compound according to claim 1 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
3. The composition according to claim 2 , wherein the compound is formulated for oral administration.
4. A method for treating cancer in a patient in need thereof, comprising the step of administering to said patient a compound of the following structure:
or a pharmaceutically acceptable salt thereof wherein the cancer is selected from colorectal cancer, lung cancer, melanoma, pancreatic cancer, and thyroid cancer.
5. The method of claim 4 , wherein the cancer is colorectal cancer.
6. The method of claim 5 , wherein the colorectal cancer is RAS-mutated.
7. The method of claim 4 , wherein the cancer is lung cancer.
8. The method of claim 7 , wherein the lung cancer is non-small cell lung cancer.
9. The method of claim 4 , wherein the cancer is melanoma.
10. The method of claim 4 , wherein the cancer is pancreatic cancer.
11. The method of claim 10 , wherein the pancreatic cancer is RAS-mutated.
12. The method of claim 4 , wherein the cancer is thyroid cancer.
13. The method of claim 4 , wherein the cancer is BRAF-mutated.
14. The method of claim 4 , wherein the cancer is RAS-mutated.
15. The method of claim 4 , wherein the cancer is KRAS-mutated.
16. The method of claim 4 , wherein the cancer is a MAPK-mediated cancer.
17. A compound of the following structure:
or a pharmaceutically acceptable salt thereof.